Hitachi Medical Systems Europe Holding AG
Stories about Medikament
- 2more
Sysmex Inostics publishes first feasibility study of NGS-based liquid biopsy to complement early breast cancer screening by imaging
Hamburg/Baltimore (ots) - Using Sysmex Inostics' novel SafeSEQ next-generation sequencing cell-free DNA technology, investigators from the Biomedical Research Institute of Malaga [(IBIMA)-CIMES-UMA, Malaga Spain] and collaborators have published the first pilot study to examine the use of a non-invasive liquid ...
moreVBS VetVerlag, Buchhandel und Seminar GmbH
World's Elite Specialists in Veterinary Rehabilitation- and Sports Medicine Meet in Ghent - Eagerly Awaited Standard Work is Going to be Presented by the Main Authors
moreSysmex obtains Japanese manufacturing and marketing approval for the first blood-based RAS mutation testing for colorectal cancer
Kobe, Japan (ots) - Sysmex Corporation has obtained Japanese manufacturing and marketing approval for the OncoBEAM(TM) RAS CRC Kit, used for blood-based circulating tumor DNA (ctDNA) molecular testing of mutations in the RAS gene for advanced colorectal cancer patients. With clinically-validated high sensitivity and ...
moreWorld's Largest Import Contract for Pharmaceutical Cannabis within EU
German Farmako secures 50 tonnes of flowers and oils from Polish company Pharmacann Polska over the next four years, generating several hundred Million Euros of revenue. This is the biggest Cannabis contract to date, and the first big contract without the participation of a ...
moreSysmex Inostics' OncoBEAM(TM) demonstrates clinical validity and superior performance versus pan-cancer NGS for blood-based mutation detection for hepatocellular carcinoma
Hamburg, Germany (ots) - Data recently published in Clinical Cancer Research (http://ots.de/0ZGZkf) the advantages of using an ultra-high sensitivity test for detection of mutations which may predict therapeutic efficacy for hepatocellular carcinoma (HCC). Sysmex Inostics' OncoBEAM technology, a highly clinically ...
more
Technische Universität München
Test predicts outcome of hay fever therapies
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22731 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/detail/article/35000/ NEWS RELEASE Test predicts outcome of hay fever therapies Allergy researchers look into molecular processes in hyposensitization to pollen Allergen-specific immunotherapy can make everyday life ...
moreSysmex Inostics' OncoBEAM(TM) liquid biopsy technology demonstrates utility for clinical management of melanoma patients undergoing treatment with targeted therapy and immune checkpoint inhibitors
Hamburg, Germany (ots) - Sysmex Inostics, a pioneer in blood-based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology, is pleased to announce publication of a study in the Journal of Molecular Oncology highlighting the important clinical value of blood-based ctDNA mutation testing to ...
more